Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs Heron Therapeutics Inc (HRTX) Price & Performance

Hewlett Packard Enterprise CoTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs Heron Therapeutics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $55.96 (market cap $72.01B), while Heron Therapeutics Inc trades at $0.33 (market cap $61.47M). The key difference: Hewlett Packard Enterprise Co is far larger — about 1171.5× Heron Therapeutics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HPEHRTX
Market Cap
$72.01B$61.47M
Sector
TechnologyHealth
52-Week High
$56.14$1.49
52-Week Low
$20.01$0.32
Enterprise Value
$87.96B$168.21M
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.

The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX